Lemon biology completes nearly 200 million yuan A round of new financing.

On March 4th, Shenzhen Laiman Biotechnology Co., Ltd. announced the completion of nearly 200 million yuan in Series A funding. This round of funding was led by Guangdong Finance Holdings' subsidiary Guangdong Finance Zhongyin Joint Investment and Jingtai Technology, with additional participation from Mining Star, Mony Valley, Tailong Investment, Zhongshan Venture Capital, and individual financial investors, while existing shareholder Fuhui Venture Capital continued to invest. The raised funds will be primarily used to advance the Phase I clinical research of ultra-low-dose metabolism-enhanced CAR-T cell therapy, accelerate the research and validation of automated production processes, and commence clinical transformation of metabolism-enhanced solid tumor cell therapy drugs.